Revolution Medicines has announced positive interim results from the Phase III RASolute 302 trial of its pan-RAS inhibitor, daraxonrasib (RMC-6236), for the second-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC). The study met its primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) compared to investigator's choice of chemotherapy. In the overall patient population, daraxonrasib nearly doubled median OS to 13.2 months versus 6.7 months for the control group.

Daraxonrasib is an oral, non-covalent inhibitor designed to target multiple common RAS mutations. The positive outcome validates a significant strategic bet by Revolution Medicines, which raised USD 2 billion in June 2025 specifically to advance the global development of this candidate. The drug has received breakthrough therapy (BTD) and orphan drug (ODD) designations int the US.

PharmCube's NextBiopharm® database shows that daraxonrasib features the furthest development among Ras×Cyp molecular glues. Click here to request a free trial for NextBiopharm®.